Letters to the Editor
Vol. 16 No. 1 (2024): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
https://doi.org/10.4084/MJHID.2024.047

Evaluation of VTE-PREDICT risk score in patients receiving low-dose DOACs for venous thromboembolism (VTE) secondary prophylaxis

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: April 30, 2024
1051
Views
879
Downloads
56
HTML
VTE Predict score, Direct oral anticoagulants (DOACs), Key words: direct oral anticoagulants, thrombophilia, thromboembolism, venous thrombosis

Authors

Alessandro Laganà
Array, Italy.
Giovanni Manfredi Assanto
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy, Italy.
Mauro Passucci
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy, Italy.
Cristina Santoro
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy, Italy.
Antonio Chistolini
chistolini@bce.uniroma1.it
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy, Italy.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
De Winter MA, Büller HR, Carrier M, Cohen AT, Hansen JB, Kaasjager KAH, Kakkar AK, Middeldorp S, Raskob GE, Sørensen HT, Visseren FLJ, Wells PS, Dorresteijn JAN, Nijkeuter M; VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 Apr 7;44(14):1231-1244.
Laganà A, Assanto GM, Masucci C, et al. Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up. Mediterr J Hematol Infect Dis. 2024;16(1):e2024020.

How to Cite



“Evaluation of VTE-PREDICT risk score in patients receiving low-dose DOACs for venous thromboembolism (VTE) secondary prophylaxis ” (2024) Mediterranean Journal of Hematology and Infectious Diseases, 16(1), p. e2024047. doi:10.4084/MJHID.2024.047.
Copyright (c) 2024 Alessandro Laganà, Giovanni Manfredi Assanto, Mauro Passucci, Cristina Santoro, Antonio Chistolini Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.